Evidence map›Paper›PMID 39527205›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2025

Assessing Drug Sensitivity in Fission Yeast Using Half-Maximal Inhibitory Concentration (IC50) Assays.

Mohammed Ayan Chhipa, Samantha A Sanayhie, Sarah A Sabatinos

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mohammed Ayan ChhipaMolecular Science Program, Yeates School of Graduate Studies, Toronto Metropolitan University, Toronto, ON, Canada.
Samantha A SanayhieDepartment of Chemistry and Biology, Yeates School of Graduate Studies, Toronto Metropolitan University, Toronto, ON, Canada.
Sarah A SabatinosMolecular Science Program, Yeates School of Graduate Studies, Toronto Metropolitan University, Toronto, ON, Canada. ssabatinos@torontomu.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fission yeast is an excellent model organism in which to study mammalian drug sensitivities. In addition to building a mechanistic picture of drug effect, fission yeast screens may be valuable in determining compounds that show synthetic lethality effects. While compounds might be screened for a variety of phenotypes, an effective method is to detect the proliferative effects of a new compound on a yeast culture. This is traditionally performed in acute viability assays or spot tests; both methods require some knowledge of concentration to observe an effect. Mammalian cell culture experiments that assess proliferation to indicate drug dose and effect are well described. However, differences between S. pombe growth characteristics and mammalian cells mean that importing a mammalian viability assay requires consideration of potential effects on fission yeast biology. We describe the half-maximum inhibitory (IC50) dose as a method of rapid proliferation effect screening. IC50 determination is performed on liquid cultures in 96-well plates and may be developed for initial compound library uses or in synthetic lethality screening of drug effects.

Indexed as

Inhibitory Concentration 50SchizosaccharomycesAntifungal AgentsDose-Response Relationship, DrugDrug Evaluation, PreclinicalMicrobial Sensitivity TestsAntifungal AgentsCompound screeningFission yeastHalf-maximal effective concentration (EC50)Half-maximal inhibitory concentration (IC50)ProliferationSchizosaccharomyces pombeSynthetic lethalityViability

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.